

Viking Therapeutics

08:20 01 Oct 2018

Viking Therapeutics stock rises on positive trial results for treatment of hip fractures

Viking Therapeutics Inc (NASDAQ:VKTS) shares climbed on Monday after the company reported positive results in a Phase 2 study of a treatment for people who suffered from hip fractures.

The company said in a statement the trial "achieved its primary endpoint" after treatment of VK5211, its lead treatment for musculoskeletal disorders, in results presented at the American Society for Bone and Mineral Research's annual meeting held over the weekend in Quebec, Canada.

A total of 108 patients were randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks.

Shares of Viking Therapeutics rose 2.47% in the Monday premarket to \$17.85, having closed on Friday down 2.35% at \$17.42.

READ: Maxim bullish on latest data for Viking Therapeutics' key drug to fight fatty liver disease

"It is striking that these increases were coupled with reductions in fat mass, indicating a favorable shift in overall body composition," said Brian Lian, the CEO of Viking.

"We are pleased with the safety and tolerability of VK5211 in this study, with no drug-related serious adverse events observed and no clinically meaningful changes in important markers such as hemoglobin, red blood cell counts and coagulation factors," he added.

The company believes VK5211 has the potential to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is based in San Diego, California.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

Price: 4.53

Market Cap: \$328.71 m

1 Year Share Price Graph



March 2019 September 2019 March 2020

Share Information

Code: VKTX

Listing: NASDAQ

52 week	High	Low
	11.02	3.27

Sector: Pharma & Biotech

Website: www.vikingtherapeutics.com

Company Synopsis:

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

action@proactiveinvestors.com

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.